

ASTRO School of Radiation Oncology

Online CME/SAM

Biosketch Information

Minesh Mehta, M.D.
Professor
University of Wisconsin
School of Medicine and Public Health

Brief Description of Responsibilities:

Dr. Minesh Mehta is a professor at the University of Wisconsin, School of Medicine and Public Health. His research interests are primarily in the areas of tomotherapy, incorporating advanced imaging in radiotherapy treatment planning, CNS malignancies, lung cancer, pediatric neoplasms, stereotactic radiosurgery, radiosensitization, combined modality therapies, altered fractionation, cost-effectiveness, and outcomes research. Dr Mehta is the PI for an NIH-funded Tomotherapy Program Project Grant. Within the context of CNS neoplasms, his particular expertise is in setting up and running multidisciplinary clinics, conducting national multimodality protocols, participating in national organizational strategies for managing these tumors and developing radiosurgery systems and protocols. In addition, within this context, he has developed 3-D/conformal techniques as well as interstitial brachytherapy expertise. Dr Mehta has run numerous multimodality clinical trials at the national level for both adult and pediatric CNS neoplasms. Current major thrust areas include developing molecularly-targeted agents as radiosensitizers for CNS tumors, such as the EGFR pathway, PKC, angiogenesis, etc. He is also the PI for an ongoing international Phase III trial of Motexafin-Gadolinium, a novel radiosensitizer, being evaluated in brain metastases patients. He is engaged in clinical trials combining Temozolomide with radiation therapy for CNS tumors. In addition, Dr Mehta is working with topoisomerase I inhibitors as radiosensitizers, for thoracic neoplasms, particularly small cell lung cancer. For the latter, he has developed a unique hyperfractionated, accelerated regimen, which has been tested in a national trial. As far as pediatric neoplasms are concerned, his major research focus has been on medulloblastoma. Outcomes research, with specific emphasis on cost-effectiveness, quality of life and neurocognitive function has been another important area of activity.

Educational Preparation: University of Zambia, Medicine and Surgery, 1981

Internship: Ndola Central Hospital, Zambia, 1983

Residency: University of Wisconsin

Degree: M.D.

Major Area of Study: Radiation Oncology

Year Earned: 1988

Select Papers:

Mehta MP, Khuntia D (Nov 2005) Current strategies in whole-brain radiation therapy for brain metastases., *Neurosurgery*, 57 (5 Suppl), S33-44; discussion

[Abstract](#)

Hong TS, Mehta MP, Boyett JM, Donahue B, Rorke LB, Zeltzer PM (Oct 2005) Patterns of treatment failure in infants with primitive neuroectodermal tumors who were treated on CCG-921: a phase III combined modality study., 45 (5), 676-82

[Abstract](#)

Langer CJ, Mehta MP, Current Management of Brain Metastases, With a Focus on Systemic Options., *Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology.*, 23(25), 6207-19, Sep 2005 [Abstract](#)

Packer RJ, Krailo M, Mehta M, Warren K, Allen J, Jakacki R, Villablanca JG, Chiba A, Reaman G (Sep 2005) Phase 1 study of concurrent RMP-7 and carboplatin with radiotherapy for children with newly diagnosed brainstem gliomas., 104 (6), 1281-7 [Abstract](#)

Tsao MN, Mehta MP, Whelan TJ, Morris DE, Hayman JA, Flickinger JC, Mills M, Rogers CL, Souhami L (Sep 2005) The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma., 63 (1), 47-55 [Abstract](#)

Cloughesy TF, Kuhn J, Robins HI, Abrey L, Wen P, Fink K, Lieberman FS, Mehta M, Chang S, Yung A, DeAngelis L, Schiff D, Junck L, Groves M, Paquette S, Wright J, Lamborn K, Sebt SM, Prados M (Sep 2005) Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study., 23 (27), 6647-56

[Abstract](#)